investors Relations

BenevolentAI

Business
Overview

BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

AI-Enabled
Drug Discovery

BenevolentAI has a proven track-record of scientifically validated discoveries. The Benevolent Platform™ powers  a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI also identified Eli Lilly's baricitinib as a repurposing drug candidate for COVID-19, which has been authorised for emergency use by the FDA.

disease area
target id
chemistry & lead optimization
preclinical
clinical
BEN2293 | atopic dermatitis
BEN8744 | ulcerative colitis
BEN9160 | amyotrophic lateral sclerosis
glioblastoma multiforme
inflammatory bowel diseases
atopic dermatitis
ulcerative colitis
amyotrophic lateral sclerosis
inflammatory bowel diseases
glioblastoma miltiforme
View Full Pipeline

Press Releases

BenevolentAI & Odyssey Combination

Presentations & Webcasts

Corporate Governance

Press Releases
& Events

all press releases→

Latest News

Jan 13, 2023

Dec 21, 2022

BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.

Events

Jan 18, 2023

Join the BenevolentAI team at the World Economic Forum’s Annual Meeting in Davos in January 2023 to discuss the impact of AI on healthcare and drug discovery.

Jan 9, 2023

Join our CEO, Joanna Shields, at the 41st Annual J.P. Morgan Healthcare Conference.